Definium Therapeutics (NASDAQ:DFTX) CEO Sells $1,315,236.24 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 29,208 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Definium Therapeutics Stock Performance

Shares of DFTX opened at $44.95 on Monday. The stock’s 50-day moving average is $24.59 and its two-hundred day moving average is $19.41. The stock has a market cap of $4.48 billion, a PE ratio of -18.05 and a beta of 2.37. Definium Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.01. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities analysts forecast that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DFTX. Piper Sandler reiterated an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Tuesday, April 21st. Robert W. Baird lifted their price target on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 23rd. Finally, Needham & Company LLC lifted their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $47.08.

Institutional Trading of Definium Therapeutics

Hedge funds have recently made changes to their positions in the stock. Palumbo Wealth Management LLC increased its stake in shares of Definium Therapeutics by 18.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock worth $522,000 after buying an additional 6,073 shares during the last quarter. Flagship Harbor Advisors LLC bought a new position in Definium Therapeutics during the 4th quarter valued at $117,000. Bay Rivers Group boosted its stake in Definium Therapeutics by 14.3% during the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after acquiring an additional 2,000 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in Definium Therapeutics during the 3rd quarter worth $107,000. Finally, Caxton Associates LLP acquired a new position in Definium Therapeutics during the 3rd quarter worth $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.